Screener
Nuvectis Pharma, Inc. NVCT Financing Cash Flow
Financing Cash Flow at other companies
Other financials
Where this comes from
Reported directly by Nuvectis Pharma, Inc. in its filing.
Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInFinancingActivities.
The source filing: Nuvectis Pharma, Inc.’s 10-Q, filed May 5, 2026.
- Filed
- May 5, 2026, 9:03 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001104659-26-055318
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Issuance costs related to At-the-market offering | — | (41) |
| Proceeds from public offering | — | 15,525 |
| Issuance costs related to public offering | — | (1,252) |
| Net cash provided by financing activities | $7 | $15,505 |
| (DECREASE)/INCREASE IN CASH AND CASH EQUIVALENTS | $(6,504) | $11,331 |
| CASH AND CASH EQUIVALENTS AT BEGINNING OF PERIOD | $31,634 | $18,533 |
| CASH AND CASH EQUIVALENTS AT END OF PERIOD | $25,130 | $29,864 |
| Supplemental noncash disclosure of investing and financing activities: |
Item 1. Financial Statements
FAQ
- What is Nuvectis Pharma, Inc.'s financing cash flow?
- Nuvectis Pharma, Inc. (NVCT) reported financing cash flow of $7K in Q1 2026.
- How has Nuvectis Pharma, Inc.'s financing cash flow changed year-over-year?
- Nuvectis Pharma, Inc.'s financing cash flow decreased by 100.0% year-over-year, from $15.51M to $7K.
- What is the long-term trend for Nuvectis Pharma, Inc.'s financing cash flow?
- Over 2 years (2023 to 2025), Nuvectis Pharma, Inc.'s financing cash flow has grown at a 38.9% compound annual growth rate (CAGR), from $15.09M to $29.11M.
- What does financing cash flow mean?
- Total net cash provided by or used in financing activities — debt issuance/repayment, equity transactions, and dividend payments.
Ask your AI about Nuvectis Pharma, Inc.'s financing cash flow.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude